The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
What is HCC? Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide, and one of the most common causes of cancer death. High mortality rates were reported in Asia and Africa, especially in less-developed regions. Surgical resection or transplantation of liver offers the best prognosis among other limited treatments, but only 15% of HCC patients are suitable for surgical intervention after initial diagnosis. Non-surgical treatment is still in demand; however, most forms of HCC are highly radio- and chemo-resistant and desirable therapeutic outcome is often elusive in clinical cases. Therefore, the development of new therapeutic agents for HCC patients is a priority.
Latest pub Oct 4th. Abstract: Angiogenesis plays an important role in hepatocellular carcinoma (HCC), the inhibition of which is explored for cancer prevention and treatment. The dietary phytochemical sulforaphane (SFN) is known for its anti-cancer properties in vitro and in vivo; but until now, no study has focused on the role of SFN in HCC tumor angiogenesis. In the present study, in vitro cell models using a HCC cell line, HepG2, and human endothelial cells, HUVECs, as well as ex vivo and in vivo models have been used to investigate the anti-tumor and anti-angiogenic effect of SFN. The results showed that SFN decreased HUVEC cell viability, migration and tube formation, all of which are important steps in angiogenesis. More importantly, SFN markedly supressed HepG2-stimulated HUVEC migration, adhesion and tube formation; which may be due to its inhibition on STAT3/HIF-1α/VEGF signalling in HepG2 cells. In addition, SFN significantly reduced HepG2 tumor growth in a modified chick embryo chorioallantoic membrane (CAM) assay, associated with a decrease of HIF-1α and VEGF expression within tumors. Collectively, these findings provide new insights into the inhibitory effect of SFN on HCC tumor angiogenesis as well as tumor growth, and indicate that SFN has potential for the prevention and treatment of HCC. Full article: https://www.nature.com/articles/s41598-017-12855-w
This BB has been very quiet for months with the sp down in the 16's then all of a sudden just after lunchtime yesterday....the buying kicked off and people arrived here. Cant find anything on the web re new news. Words out in the US re something really positive? Any thoughts?
Dipping! It was sub 15 2 days ago....way undervalued.
I've been invested here over 12 months waiting patiently for the potential to be slowly revealed....and boom, lunchtime yesterday all hell breaks lose and the cavalry arrive? What happened yesterday lunchtime? Welcome aboard everyone. :)
Agreed...this study was pub Oct 4th. Abstract: Angiogenesis plays an important role in hepatocellular carcinoma (HCC), the inhibition of which is explored for cancer prevention and treatment. The dietary phytochemical sulforaphane (SFN) is known for its anti-cancer properties in vitro and in vivo; but until now, no study has focused on the role of SFN in HCC tumor angiogenesis. In the present study, in vitro cell models using a HCC cell line, HepG2, and human endothelial cells, HUVECs, as well as ex vivo and in vivo models have been used to investigate the anti-tumor and anti-angiogenic effect of SFN. The results showed that SFN decreased HUVEC cell viability, migration and tube formation, all of which are important steps in angiogenesis. More importantly, SFN markedly supressed HepG2-stimulated HUVEC migration, adhesion and tube formation; which may be due to its inhibition on STAT3/HIF-1α/VEGF signalling in HepG2 cells. In addition, SFN significantly reduced HepG2 tumor growth in a modified chick embryo chorioallantoic membrane (CAM) assay, associated with a decrease of HIF-1α and VEGF expression within tumors. Collectively, these findings provide new insights into the inhibitory effect of SFN on HCC tumor angiogenesis as well as tumor growth, and indicate that SFN has potential for the prevention and treatment of HCC. Full article: https://www.nature.com/articles/s41598-017-12855-w
Yes but only a small delay and we should know first read on results which if positive will attract much bigger investors. It's not for the day traders and they have also taken another step forward.
Used to be invested here but im glad I sold out a while back. Zak Mir would appear to be only interested in himself and not his shareholder's. Truly pathetic.
Just one string to our bow :) From today's FT - Orphan drugs attract rich returns for pharmaceuticals: https://www.ft.com/content/2016a758-d674-11e6-944b-e7eb37a6aa8e From an EVG RNS last year: Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce that the US Food & Drug Administration ("FDA") has granted the Company orphan drug designation for the use of stabilised sulforaphane for the treatment of subarachnoid haemorrhage ("SAH"). Dr Stephen Franklin, Evgen Pharma's CEO, commented: "The receipt of orphan drug designation in SAH is highly significant for Evgen Pharma and for our clinical programme in SAH, a devastating condition with high unmet clinical need. Evgen's SFX-01, has the potential to represent the first step-change improvement in the treatment of SAH in more than 20 years in that it targets the principal drivers of the delayed vasospasm. Recruitment in our Phase II study of SFX-01 in SAH remains on track and we look forward to the results of the study in due course."
Shares in Evgen Pharma plc (LON:EVG) soared on Tuesday afternoon after the drug developer revealed it had been granted a US patent which “significantly broadens and extends [its] intellectual property” around its lead product SFX-01. Shares were up 14% to 25p shortly before the close of play in London. The new patent covers the manufacturing process of SFX-01 – a synthetic version of the naturally occurring compound sulforaphane – and runs until 2033. “This patent grant extends our intellectual property protection in the world's largest pharmaceutical market and is the first of a potentially broad geographical spread of patents that are pending in Europe, Japan, India, China, Canada, Brazil and Australia,” said chief executive Stephen Franklin. Under the terms of the licence agreement with PharmAgra Labs Inc – the US lab which invented the compound – Evgen holds the exclusive worldwide rights to the patent. Evgen is currently conducting two phase II trials of SFX-01; one in advanced breast cancer and the other in a type of stroke called subarachnoid haemorrhage. Today’s patent grant comes a day after Evgen signed a services agreement with a consortium of Cheshire-based drug development firms. The group aims to help clients turn promising molecules and compounds into valued medicines, which Evgen hopes to do with SFX-01.
I have done days ago and have not had a reply? Also he says DM him on twitter but you can't?
I have done and have not had a reply?
It's now time for him to let us long suffering shareholders what the hell is going on. We've still not been told why the rto was cancelled, why the nomad resigned or why we were suspended!? Completely taking the **** now. Is it also correct his father took £50k for setting up the loan to big sofa?! I and many other pi's locked in here want answers Mr Reynolds and to keep us in the dark with no news when many invested here because of YOUR involvement is outrageous. Tell us where going on please Mr Reynolds.
WTF? what's this about £50k going to AR's Dad!!! I would advise Mr Reynolds to inform us shareholders who bought in further due to his involvement here, what the hell's going on....otherwise his appearance at the UK investor show will become the most embarrassing moment of his life.
If AR throws in the towel then his reputation will be in tatters as I for one invested more because if his involvement.
This would not appear to be the case with IG. My delisted DAN shares that have been there for ages are still in my ISA account as my NEW shares are?
I've applied to join the group . Thanks Rich
I did not receive that email? Can the action group tell me why please?